MYCOLab Ai Logo - gold and army green

Phallus indusiatus Extracts Promoted MCF-7 Apoptosis Under TNFα-induced Tumor Microenvironment by Attenuating NF-kappaB and Akt Activation

Summary

Bamboo mushroom extracts show promise in helping treat breast cancer by making cancer cells more sensitive to chemotherapy drugs. The mushroom reduces inflammation and blocks protective signals in cancer cells, making them more likely to die. This research suggests bamboo mushroom could be a helpful supplement for breast cancer patients, especially when used alongside standard cancer treatments.

Background

Breast cancer remains a significant health concern with higher incidence in Thailand and Asia. TNFα-induced tumor microenvironment and chemoresistance present challenges in treatment efficacy. Phallus indusiatus (bamboo mushroom) has been studied for antioxidant, neuroprotective, and anti-inflammatory properties.

Objective

To evaluate the anti-inflammatory and anticancer effects of Phallus indusiatus extracts in modulating inflammatory microenvironments and sensitizing lapatinib-induced cytotoxicity in breast cancer cells.

Results

P. indusiatus extracts demonstrated dose-dependent anti-inflammatory effects by reducing NO production. Under TNFα-induced inflammatory conditions, extracts reduced MCF-7 cell viability and sensitized lapatinib-induced cytotoxicity with increased apoptosis. Mechanistically, co-treatment attenuated NF-kappaB and Akt phosphorylation in dose-dependent manner. Notably, dried mycelium exhibited highest antioxidant and anti-inflammatory activity.

Conclusion

Phallus indusiatus extracts show potential as supplementary food for breast cancer patients by enhancing chemotherapy efficacy through NF-kappaB and Akt pathway inhibition in inflammatory microenvironments. These findings support further investigation of mushroom-derived compounds as adjuvant therapies.
  • Published in:Asian Pacific Journal of Cancer Prevention,
  • Study Type:In vitro Experimental Study,
  • Source: PMID: 40022692, DOI: 10.31557/APJCP.2025.26.2.479
Scroll to Top